For the Inventor, By the Inventor

Enter assignee name

Lexington, MA, United States of America

Curis, Inc.

USPTO Granted Patents = 141

CIPO Patents = 9

EPO Patents = 30

Trademarks = 3

Forward Citations = 1,443

Loading Chart...

Loading Chart...

142 inventors (with patents filed for the assignee):

Xiong Cai (46 out of 73 patents)

Changgeng Qian (43 out of 51 patents)

Haixiao Zhai (36 out of 39 patents)

4. Charles M Cohen (17 out of 60 patents)

5. David C Rueger (16 out of 83 patents)

6. Chengjung Lai (15 out of 15 patents)

7. Oivin M Guicherit (15 out of 16 patents)

8. Lee L Rubin (14 out of 30 patents)

9. Hermann Oppermann (13 out of 88 patents)

10. Stephen Colin Price (13 out of 55 patents)

11. Roy H L Pang (13 out of 21 patents)

12. Edward Andrew Boyd (13 out of 33 patents)

13. Thangavel Kuberasampath (11 out of 67 patents)

14. Kuber T Sampath (10 out of 46 patents)

15. Stephen Gould (10 out of 10 patents)

Core Competencies:

Phosphoinositide 3-Kinase Inhibitors

HSP90 Inhibitors

Hedgehog Antagonists

Combination Therapy

Immunomodulators

EGFR Inhibitors

Zinc Binding Moiety

Mutant Smoothened

Cell Proliferation Regulators

Crystal Forms

Pyridyl Inhibitors

Hematological Disorders

141 patents: Sort by Forward Citations

1. 12403142 - Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety (2025-09-02),

2. 12252475 - Crystal forms of immunomodulators (2025-03-18),

3. 12178821 - Combination therapies for the treatment of cancer (2024-12-31),

4. 12064418 - Conjoint therapies for immunomodulation (2024-08-20),

5. 11939306 - Crystal forms of immunomodulators (2024-03-26),

6. 11654136 - Phosphoinositide 3-kinase inhibitor with a zinc binding moiety (2023-05-23),

7. 11643401 - Crystal forms of immunomodulators (2023-05-09),

8. 11597732 - Phosphoinositide 3-kinase inhibitors with a zinc binding moiety (2023-03-07),

9. 11497735 - Conjoint therapies for immunomodulation (2022-11-15),

10. 11261195 - Phosphoinositide 3-kinase inhibitors with a zinc binding moiety (2022-03-01),

11. 11234986 - Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety (2022-02-01),

12. 11135205 - Phosphoinositide 3-kinase inhibitor with a zinc binding moiety (2021-10-05),

13. 11040948 - Crystal forms of immunomodulators (2021-06-22),

14. 10894795 - Phosphoinositide 3-kinase inhibitors with a zinc binding moiety (2021-01-19),

15. 10844056 - Fused amino pyridine as HSP90 inhibitors (2020-11-24),

Curis, Inc. is a biotechnology company dedicated to the discovery and development of innovative therapeutics for the treatment of cancer. With a focus on targeted therapies, Curis is committed to transforming the lives of patients through advanced research and development efforts. Through strategic collaborations and proprietary technologies, Curis is advancing a diverse pipeline of potential breakthrough treatments. For more information, please visit the Curis website.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

141 Patents

#6 in Lexington, MA

#143 in Massachusetts

#2,675 in US

#5,605 in the World

Lexington, MA, United States of America

Curis, Inc.

Forward Citations = 1,443

142 inventors:

Xiong Cai (46 out of 73 patents)

Changgeng Qian (43 out of 51 patents)

Haixiao Zhai (36 out of 39 patents)

4. Charles M Cohen (17 out of 60 patents)

5. David C Rueger (16 out of 83 patents)

Please report any incorrect information to support@idiyas.com

Loading…